Amgen’s Approach to Responsible Pricing
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
- Pricing our products according to the value they deliver
- Employs flexible pricing approaches to ensure patient access
Providing access to our medicines is an extension of Amgen’s mission to serve patients. Through our access to healthcare programs, we work with partners to expand access to our medicines and support efforts to strengthen healthcare systems to better serve patients in need worldwide.
The sale of our medicines provides us with the investment required to fund future research and development to address serious, unmet medical need to improve upon the impact that some diseases have on society and our ability to help patients live longer, healthier lives. Over the past five years, we invested over $20 billion* in R&D, with three-quarters of the molecules in our pipeline representing potential first-in-class medicines for serious diseases.